• June 3-6, 2024
  • San Diego Convention Center, California



PassPort Technologies, Inc.

Wednesday, June 05, 2024
Company Presentation
Platform for Therapeutics
Company Presentation Theater 4
PassPort Technologies is a clinical stage drug and medical device development company with its proprietary groundbreaking transdermal microporation platform, PassPort® System. The PassPort® System allows for painless and needle-free delivery of peptides/proteins, antigen/mRNA vaccines, and small molecules via skin. The leading project in our pipelines is Zolmitriptan PassPort®, Best-in-Class, for the treatment of acute migraine with interim positive results in Phase 1 clinical studies. The 2nd clinical candidate, ALC PassPort®, First-in-Class novel peptide drug, is for the treatment of Alzheimer's Disease. PassPort Technologies was founded in 2019 in San Diego, CA and is owned by Axcelead, Inc.
PassPort Technologies, Inc.
Company Website: https://passport-tech.com/
Lead Product in Development: Zolmitriptan PassPort® & ALC PassPort®
Number Of Unlicensed Products (For Which You Are Seeking Partners): Five (5) and platform technologies

Company HQ City

San Diego

Company HQ State


Company HQ Country

United States

CEO/Top Company Official

Tomoyuki Fujisawa (President & CEO)

Development Phase of Primary Product

Phase I
Primary Speaker
Jeremiah Meloch, BS
Business Development Representative
PassPort Technologies Inc.
Back to Session List

white squarewhite


Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.